Inhibition of angiogenesis

Details Inhibition of angiogenesis Inhibition of angiogenesis

1988-10-13

1991-02-19

Friedman, Stanley J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514177, 514178, A61K 31725, A61K 3156

Patent

active

049944436

ABSTRACT:
Angiogenesis in mammals is inhibited by administration of the active agents (1) heparin or a heparin fragment which is a hexasaccharide or larger or analogous compounds and (2) a steroid having 17.alpha.- and 21-hydroxy groups, 3- and 20-one groups, and in the 16-position hydrogen hydroxy or a methyl group, and non-toxic physiologically acceptable carboxylates, acetals, ketals and phosphates thereof.

REFERENCES:
patent: 4771042 (1989-07-01), Braughler et al.
The Merck Index, 9th edition, 1976, pp. 629-630 & 999.
Elias et al., Cancer Chemotherapy Reports, Part 1, vol. 56, No. 6, 12/72, pp. 783-785.
Elias et al., Cancer, 7/75, vol. 36, pp. 129-136.
Eichbaum Rev. Bras. de Pesquisas Med. Biol. 8(5-6): 489-496, 1975.
Grossman et al., Proc. Natl. Acad. Sci. U.S.A., vol. 78, 1176-1180 (1981).

Affiliated with

Also associated with

Rating

Inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of angiogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1143689